Lianxia Xiaopi Granules

Lianxia Xiaopi Granules is a traditional Chinese medicine formulation currently in Phase 3 clinical development for the treatment of postprandial distress syndrome (PDS), particularly in patients with "cold-heat mixed syndrome" as defined by traditional Chinese medicine. The granule formulation is being evaluated for its efficacy and safety in improving symptoms of functional dyspepsia and postprandial discomfort. Preclinical studies suggest that its pharmacological effects may be mediated through regulation of gastrointestinal function, but the precise molecular mechanism of action remains unclear. The product is being developed and trialed primarily in China, with involvement from both academic institutions and pharmaceutical companies[1][2][4].

Brand names

Lianxia Xiaopi Granules

Other names

Lianxia Xiaopi Granules连夏消痞颗粒